Estrogen Receptor Breast Cancer Completed Phase 1 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0056979 (Estrogen Receptor Breast Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01594398Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung CancerTreatment